6-tert-butyl-2-[[1-(5-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]pyridazin-3-one
C21H29N7O — CID 126924132
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-tert-butyl-2-[[1-(5-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]pyridazin-3-one
6-tert-butyl-2-[[1-(5-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]pyridazin-3-one (PubChem CID 126924132) has the molecular formula C21H29N7O and a molecular weight of 395.51 g/mol. Its IUPAC name is 6-tert-butyl-2-[[1-(5-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]pyridazin-3-one.
Molecular Properties
| Compound Name | 6-tert-butyl-2-[[1-(5-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]pyridazin-3-one |
|---|---|
| PubChem CID | 126924132 |
| Molecular Formula | C21H29N7O |
| Molecular Weight | 395.51 g/mol |
| Exact Mass | 395.24 |
| IUPAC Name | 6-tert-butyl-2-[[1-(5-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]pyridazin-3-one |
| SMILES | CC(C)c1cc(N2CCCC2Cn2nc(C(C)(C)C)ccc2=O)n2ncnc2n1 |
| InChI | InChI=1S/C21H29N7O/c1-14(2)16-11-18(28-20(24-16)22-13-23-28)26-10-6-7-15(26)12-27-19(29)9-8-17(25-27)21(3,4)5/h8-9,11,13-15H,6-7,10,12H2,1-5H3 |
| InChIKey | NVDFONWOQBHNNF-UHFFFAOYSA-N |
| XLogP | 2.77 |
| TPSA | 81.21 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 395.51 |
| LogP ≤ 5 | 2.77 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 126924132 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.